{"id":4016,"date":"2012-04-13T13:35:00","date_gmt":"2012-04-13T13:35:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=4016"},"modified":"2021-07-09T11:26:34","modified_gmt":"2021-07-09T11:26:34","slug":"adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/","title":{"rendered":"Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn’s disease accompanied by chronic myeloid leukemia"},"content":{"rendered":"
\n

Tsutomu Mizoshita<\/a> 1<\/a><\/sup>, Satoshi Tanida<\/a> 2<\/a><\/sup>, Shigeru Kusumoto<\/a> 3<\/a><\/sup>, Keiji Ozeki<\/a> 2<\/a><\/sup>, Hironobu Tsukamoto<\/a> 2<\/a><\/sup>, Masahide Ebi<\/a> 2<\/a><\/sup>, Yoshinori Mori<\/a> 2<\/a><\/sup>, Hiromi Kataoka<\/a> 2<\/a><\/sup>, Takeshi Kamiya<\/a> 2<\/a><\/sup>, Takashi Joh<\/a> 2<\/a><\/sup>,Clin J Gastroenterol. 2012 Aug;5(4):302-6.<\/p>\n<\/div>\n\n

\n

A 52-year-old woman was diagnosed with Crohn’s disease (CD) of the large intestine in May 2001. Her disease was accompanied by the development of chronic myelogenous leukemia (CML) in December 2003. Remission of her CML has been maintained up to the present with tyrosine kinase inhibitors. Clinical and endoscopic remission of the patient’s CD was maintained with salazosulfapyridine (3000 mg\/day) and occasional prednisolone (\u226420 mg\/day) from 2001 to 2010. However, in December 2010 the patient complained of abdominal pain and diarrhea more than 10 times a day. Endoscopy showed serpiginous (snake-like) ulcers in the transverse colon and aphthous ulcers in the sigmoid colon. Intensive granulocyte and monocyte adsorptive apheresis (GMA) (two sessions per week, total of ten sessions) was performed, and the CD activity index (CDAI) decreased from 259 to 175. Six adalimumab injections were administered to improve the remaining inflammatory mucosa. Two months after induction therapy with adalimumab, the CDAI decreased from 175 to 107 without side effects. Endoscopy revealed mucosal healing of the colonic inflammatory lesions. We experienced a case of a patient with CD accompanied by CML. We successfully treated the patient by a combination of intensive GMA and adalimumab<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/26182398\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Tsutomu Mizoshita 1, Satoshi Tanida 2, Shigeru Kusumoto 3, Keiji Ozeki 2, Hironobu Tsukamoto 2, Masahide Ebi 2, Yoshinori Mori 2, Hiromi Kataoka 2, Takeshi Kamiya 2, Takashi Joh 2,Clin J Gastroenterol. 2012 Aug;5(4):302-6. A 52-year-old woman was diagnosed with Crohn’s disease (CD) of the large intestine in May 2001. Her disease was accompanied by the development of chronic myelogenous leukemia (CML) in December 2003. Remission of her CML has been maintained up to […]<\/p>\n","protected":false},"template":"","scientific_tags":[215,245,244,147,243,311],"class_list":["post-4016","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-adalimumab","scientific_tags-cdai","scientific_tags-chronic-myeloid-leukemia","scientific_tags-clinical-remission","scientific_tags-complication","scientific_tags-special-situations"],"acf":[],"yoast_head":"\nAdalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Tsutomu Mizoshita 1, Satoshi Tanida 2, Shigeru Kusumoto 3, Keiji Ozeki 2, Hironobu Tsukamoto 2, Masahide Ebi 2, Yoshinori Mori 2, Hiromi Kataoka 2, Takeshi Kamiya 2, Takashi Joh 2,Clin J Gastroenterol. 2012 Aug;5(4):302-6. A 52-year-old woman was diagnosed with Crohn’s disease (CD) of the large intestine in May 2001. Her disease was accompanied by the development of chronic myelogenous leukemia (CML) in December 2003. Remission of her CML has been maintained up to […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:26:34+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/\",\"name\":\"Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2012-04-13T13:35:00+00:00\",\"dateModified\":\"2021-07-09T11:26:34+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/","og_locale":"es_ES","og_type":"article","og_title":"Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia - Adacyte","og_description":"Tsutomu Mizoshita 1, Satoshi Tanida 2, Shigeru Kusumoto 3, Keiji Ozeki 2, Hironobu Tsukamoto 2, Masahide Ebi 2, Yoshinori Mori 2, Hiromi Kataoka 2, Takeshi Kamiya 2, Takashi Joh 2,Clin J Gastroenterol. 2012 Aug;5(4):302-6. A 52-year-old woman was diagnosed with Crohn’s disease (CD) of the large intestine in May 2001. Her disease was accompanied by the development of chronic myelogenous leukemia (CML) in December 2003. Remission of her CML has been maintained up to […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:26:34+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/","name":"Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2012-04-13T13:35:00+00:00","dateModified":"2021-07-09T11:26:34+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/adalimumab-therapy-following-granulocyte-and-monocyte-adsorptive-apheresis-in-a-patient-with-crohns-disease-accompanied-by-chronic-myeloid-leukemia\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/4016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=4016"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=4016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}